5-alpha-reductase Inhibitors
2 drugsAbout 5-alpha-reductase
5-alpha-reductase is an enzyme that converts testosterone to dihydrotestosterone (DHT), a more potent androgen. DHT plays a key role in male characteristic development and maintenance. Overproduction of DHT can contribute to conditions addressed by current medications.
While there is no genetic evidence directly linking 5-alpha-reductase to specific diseases, its role in androgen metabolism makes it a therapeutic target. Inhibiting 5-alpha-reductase can reduce DHT levels, addressing related conditions.
Two drugs targeting 5-alpha-reductase are FDA-approved: JALYN and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE. Both are small molecule drugs and are used in 'other' therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Bladder Cancer with only 1 trials.
Top Drugs
WAYLIS THERAP and Aurobindo Pharma are the companies with approved drugs targeting this enzyme.
The market is unconcentrated, suggesting relatively low barriers to entry for new competitors.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 5-alpha-reductase, using small molecule modality.
Exploring alternative modalities like antibodies could provide a competitive advantage.
Clinical Trials 124 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 29 | 2 | 3 | 94% |
| Phase 2 | 27 | 15 | 5 | 7 | 75% |
| Phase 3 | 27 | 15 | 7 | 5 | 68% |
| Phase 4 | 36 | 26 | 7 | 3 | 79% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2010 - 2010)
The first drug was approved in 2010 (JALYN), and the most recent in 2014 (DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE).
The approval timeline suggests a potential slowdown or saturation in this therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 59 clinical trials targeting 5-alpha-reductase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities